Technical Analysis for COYA - Coya Therapeutics, Inc.

Grade Last Price % Change Price Change
B 7.24 -0.55% -0.04
COYA closed down 0.55 percent on Wednesday, December 6, 2023, on 6.15 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Reversed from Down about 19 hours ago
Possible Pocket Pivot about 19 hours ago
Down 10% about 22 hours ago
Gap Up Closed about 23 hours ago
Reversed from Up about 23 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Coya Therapeutics, Inc. Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Immune System Cell Therapy Metabolic Disease Amyotrophic Lateral Sclerosis T Cells Exosome Frontotemporal Dementia Medicinal Products

Is COYA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

See more COYA news...


Indicator Value
52 Week High 8.0
52 Week Low 3.21
Average Volume 47,128
200-Day Moving Average 4.46
50-Day Moving Average 4.95
20-Day Moving Average 5.56
10-Day Moving Average 6.04
Average True Range 0.56
RSI (14) 78.68
ADX 26.89
+DI 39.73
-DI 6.94
Chandelier Exit (Long, 3 ATRs) 6.31
Chandelier Exit (Short, 3 ATRs) 6.09
Upper Bollinger Bands 7.21
Lower Bollinger Band 3.91
Percent B (%b) 1.01
BandWidth 59.23
MACD Line 0.56
MACD Signal Line 0.34
MACD Histogram 0.2217
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.49
Resistance 3 (R3) 9.49 8.75 9.12
Resistance 2 (R2) 8.75 8.17 8.75 8.99
Resistance 1 (R1) 7.99 7.82 7.62 7.99 8.86
Pivot Point 7.25 7.25 7.06 7.25 7.25
Support 1 (S1) 6.49 6.67 6.12 6.49 5.62
Support 2 (S2) 5.75 6.32 5.75 5.49
Support 3 (S3) 4.99 5.75 5.37
Support 4 (S4) 4.99